ArticleMedicina (Kaunas, Lithuania)2026
First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score.
Mert Tohumcuoğlu, Abdullah Evren Yetişir, Zafer Ufuk Cinkara, Mehmet Türker, Alpay Düşgün, Cem Mirili, Deniz Tazeoğlu, Tolga Köşeci, Ali Oğul, Mahmut Büyükşimşek
Abstract read
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Mert TohumcuoğluDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0003-3653-4429 Abdullah Evren YetişirDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.
Zafer Ufuk CinkaraDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.
Mehmet TürkerDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0003-4163-917X Alpay DüşgünDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0003-2994-9191 Deniz TazeoğluDepartment of Surgical Oncology, Osmaniye State Hospital, Osmaniye 80010, Türkiye.
Tolga KöşeciDepartment of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
Ali OğulDepartment of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33343, Türkiye.ORCID 0000-0003-4886-7060 Mahmut BüyükşimşekDepartment of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.ORCID 0000-0001-6356-9059 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AminopyridinesBreast NeoplasmsLetrozolePiperazinesPurinesPyridinesAgedAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm MetastasisPostmenopausePrognosisAminopyridinesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLetrozolepalbociclibPiperazinesPurinesPyridinesReceptors, EstrogenReceptors, ProgesteroneribociclibCDK4/6 inhibitorcomposite risk scorehormone receptor-positive/HER2-negative metastatic breast cancerpalbociclibpan-immune-inflammation valueprogesterone receptorribociclibvisceral metastasis
Identifiers
PMID42654366
PMCPMC13515390
What OpenQuestion holds
Textmetadata
Read underepoch 390